CoChat

Durable blockade of PD-1 signaling links preclinical efficacy of sintilimab to its clinical benefit

Open access
Wang, Jie, Fei, Keke, Jing, Hua, Wu, Zhihai, Wu, Weiwei, Zhou, Shuaixiang, Ni, Haiqing, Chen, Bingliang, Xiong, Yan, Liu, Yanpeng, Peng, Bo, Yu, Dechao, Jiang, Haiping, Liu, Junjian · 2019 · mAbs
Cited by 149

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

Blockade of immune checkpoint pathways by programmed cell death protein 1 (PD-1) antibodies has demonstrated broad clinical efficacy against a variety of malignancies. Sintilimab, a highly selective, fully human monoclonal antibody (mAb), blocks the interaction of PD-1 and its ligands and has demonstrated clinical benefit in various clinical studies. Here, we evaluated the affinity of sintilimab to human PD-1 by surface plasmon resonance and mesoscale discovery and evaluated PD-1 receptor occupancy and anti-tumor efficacy of sintilimab in a humanized NOD/Shi-scid-IL2rgamma (null) (NOG) mouse model. We also assessed the receptor occupancy and immunogenicity of sintilimab from clinical studies in humans (9 patients with advanced solid tumor and 381 patients from 4 clinical studies, respectively). Sintilimab bound to human PD-1 with greater affinity than nivolumab (Opdivo®, MDX-1106) and pembrolizumab (Keytruda®, MK-3475). The high affinity of sintilimab is explained by its distinct structural binding mode to PD-1. The pharmacokinetic behavior of sintilimab did not show any significant differences compared to the other two anti-PD-1 mAbs. In the humanized NOG mouse model, sintilimab showed superior PD-1 occupancy on circulating T cells and a stronger anti-tumor effect against NCI-H292 tumors. The strong anti-tumor response correlated with increased interferon-γ-secreting, tumor-specific CD8+ T cells, but not with CD4+ Tregs in tumor tissue. Pharmacodynamics testing indicated a sustained mean occupancy of ≥95% of PD-1 molecules on circulating T cells in patients following sintilimab infusion, regardless of infusion dose. Sintilimab infusion was associated with 0.52% (2/381 patients) of anti-drug antibodies and 0.26% (1/381 patients) neutralizing antibodies. These data validate sintilimab as a novel, safe, and efficacious anti-PD-1 mAb for cancer immunotherapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1080/19420862.2019.1654303

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 149

Metadata

Authors
Wang, J., Fei, K., Jing, H., Wu, Z., Wu, W., Zhou, S., Ni, H., Chen, B., Xiong, Y., Liu, Y., Peng, B., Yu, D., Jiang, H., & Liu, J.
Venue
mAbs
Published
2019-09-03
Volume
11
Issue
8
Pages
1443-1451
ISSN
  • 1942-0862 (ISSN-L)
  • 1942-0870
OpenAlex
W2967960429
Cited by
149
References
8
FWCI
5.71
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Durable blockade of PD-1 signaling links preclinical efficacy of sintilimab to its clinical benefit. https://app.cochat.ai/papers/10.1080/19420862.2019.1654303
The paper
Wang, J., Fei, K., Jing, H., Wu, Z., Wu, W., Zhou, S., Ni, H., Chen, B., Xiong, Y., Liu, Y., Peng, B., Yu, D., Jiang, H., & Liu, J. (2019). Durable blockade of PD-1 signaling links preclinical efficacy of sintilimab to its clinical benefit. mAbs. https://doi.org/10.1080/19420862.2019.1654303

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.